Janus kinase inhibitors: between prescription authorization and reimbursability

F.R. Spinelli; F. Conti; R. Caporali; F. Iannone; F. Cacciapaglia; on behalf of the Steering Committee of the Italian Society of Rheumatology

doi:10.4081/reumatismo.2023.1627

Reumatismo (Dec 2023)

Janus kinase inhibitors: between prescription authorization and reimbursability

F.R. Spinelli,
F. Conti,
R. Caporali,
F. Iannone,
F. Cacciapaglia,
on behalf of the Steering Committee of the Italian Society of Rheumatology

Affiliations

F.R. Spinelli: Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome
F. Conti: Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome
R. Caporali: Rheumatology Unit, Department of Clinical and Community Sciences, University of Milan, ASST Gaetano Pini-CTO, Milan
F. Iannone: Rheumatology Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro
F. Cacciapaglia: Rheumatology Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro
on behalf of the Steering Committee of the Italian Society of Rheumatology

DOI: https://doi.org/10.4081/reumatismo.2023.1627
Journal volume & issue: Vol. 75, no. 4

Abstract

Read online

Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.

Janus kinase inhibitors

Published in Reumatismo

ISSN: 0048-7449 (Print); 2240-2683 (Online)
Publisher: PAGEPress Publications
Country of publisher: Italy
LCC subjects: Medicine: Internal medicine
Website: http://www.reumatismo.org

About the journal

Abstract

Keywords